Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2024-05-08 AGM Information
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Annual General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 100% confidence The document is explicitly titled "ANNUAL GENERAL MEETING OF INFANT BACTERIAL THERAPEUTICS" and details the resolutions passed during the meeting held on May 8, 2024. Key items resolved include the adoption of financial statements, dividend decisions, election/re-election of board members and committees, approval of remuneration reports, and authorization for share issuance/incentive programs. These contents directly correspond to the purpose of an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2024-05-08 English
Årsstämma i Infant Bacterial Therapeutics
AGM Information Classification · 99% confidence The document is explicitly titled "ÅRSSTÄMMA I INFANT BACTERIAL THERAPEUTICS" (Annual General Meeting in Infant Bacterial Therapeutics) and details the resolutions passed during the meeting held on May 8, 2024, such as approving financial statements, dividend decisions, board member re-elections, and remuneration. This content directly corresponds to the definition of AGM Information. Although it is a press release summarizing the event, the core subject matter is the outcome of the AGM, making AGM-R the most appropriate classification over a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), as it is the primary content, not just an announcement of an attachment.
2024-05-08 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport 1 januari – 31 mars 2024' (Interim Report for January 1 – March 31, 2024) for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on the quarterly performance. It is a full interim report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q1 2024
2024-05-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1 – March 31, 2024' for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including a balance sheet, income statement, cash flow analysis, and management commentary regarding the first quarter of 2024. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-07 English
Viktig milstolpe uppnådd - sista patienten rekryterats i Infant Bacterial Therapeutics fas 3 studie
Report Publication Announcement Classification · 98% confidence The document is a press release dated April 4, 2024, announcing a significant operational milestone: the completion of patient recruitment for the Phase 3 clinical trial ('The Connection Study') for their drug candidate IBP-9414. It includes quotes from the CEO, background information on the company (IBT), and mentions that the results are expected in Q3 2024. Crucially, at the end, it lists an 'Attached file' which is the full PDF document. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document is short (4141 chars) and primarily serves to announce that a report or information has been published (often linking to the full document), it should be classified as a Report Publication Announcement (RPA) rather than the underlying report itself (like ER or IR). This announcement is about the publication/completion of a major study milestone, not the final results or a standard periodic financial report.
2024-04-04 Swedish
Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study
Regulatory Filings Classification · 100% confidence The document is titled 'PRESS RELEASE' and announces a 'MAJOR MILESTONE ACHIEVED - LAST PATIENT ENROLLED IN INFANT BACTERIAL THERAPEUTICS' PHASE 3 STUDY'. It provides key operational updates (patient enrollment completion, expected results timeline) and includes contact information, concluding with a statement that the information is made public pursuant to the EU Market Abuse Regulation. Crucially, at the end, it lists an 'Attachment' which is a PDF of the announcement itself. Since the document is short (under 5,000 characters) and functions as an announcement about a corporate event/update rather than a comprehensive financial report (like 10-K or IR), it fits the criteria for a general regulatory announcement or a report publication announcement. Given the context of regulatory disclosure under EU MAR, 'Regulatory Filings' (RNS) is the most appropriate general category for such press releases that disseminate material, non-financial-statement information, especially when an attachment is provided, suggesting the primary purpose is dissemination rather than being the report itself. It is not a specific financial report, earnings release, or management discussion.
2024-04-04 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.